期刊
MOLECULAR PHARMACEUTICS
卷 8, 期 1, 页码 12-28出版社
AMER CHEMICAL SOC
DOI: 10.1021/mp100219n
关键词
Oncolytic adenovirus; cancer; gene therapy; virotherapy
资金
- European Research Council
- EU
- THERAD-POX
- ASCO Foundation
- HUCH Research Funds
- Sigrid Juselius Foundation
- Academy of Finland
- Biocentrum Helsinki
- University of Helsinki
Although results of cancer treatment have improved steadily, metastatic solid tumors can be cured only rarely and therefore new modalities are needed. Tumors often become apoptosis-resistant and capable of excluding drugs during therapy. Similar mechanisms of resistance apply to many treatment regimens, and cross-resistance between different chemotherapeutics often limits the treatment options. Therefore, loss of efficacy may occur simultaneously for different chemotherapeutics. One experimental strategy with an increasing amount of clinical evidence is oncolytic viruses, which replicate preferentially in tumor cells by taking advantage of cancer-specific cellular changes. Adenoviruses are the most widely clinically used oncolytic agents. Replication of oncolytic virus per se kills tumor cells, but oncolysis can also activate the immune system, which may play a role in tumor control. Viruses can be modified in a variety of ways to improve their selectivity and efficacy. The adenovirus genome can be easily engineered to incorporate different tumor targeting mechanisms and therapeutic transgenes for improved antitumor properties. Here we review the available preclinical and clinical data on use of oncolytic adenoviruses in humans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据